

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Original) A method of identifying an attenuated respiratory syncytial virus (RSV) strain that produces high yields of RSV surface glycoproteins F and G when compared with the parent A2 strain, which method comprises:  
providing a eukaryotic cell culture;  
infecting the eukaryotic cell culture with a live, attenuated RSV strain; and  
determining the glycoprotein concentration in the harvest of the culture,  
wherein at least a five-fold increase in glycoprotein concentration is an indication that the attenuated RSV strain produces high yields of RSV F and G glycoproteins when compared with the parent A2 strain.
2. (Original) The method of claim 1, wherein the identified attenuated RSV strain is the RSV mutant strain *cpts-248/404*.
3. (Original) The method of claim 1, wherein the eukaryotic cell culture is a VERO, MRC-5, FRhL, CEF or PER.C6 cell culture.
4. (Original) A process for producing purified RSV F protein comprising:  
growing eukaryotic cells infected with the RSV mutant strain *cpts-248/404* in a cultured medium at 30°C;  
solubilizing the F protein from the virus-infected cell membrane; and  
isolating and purifying the solubilized F protein.
5. (Original) The process of claim 4, wherein the isolating and purifying is effected by loading the solubilized F protein onto an ion-exchange matrix, and eluting the F protein from the ion-exchange matrix.

6. (Original) The process of claim 4, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
7. (Currently amended) A process for producing an immunogenic composition for protecting against disease caused by RSV, wherein said process comprises producing an RSV F protein by a process according to ~~either claim 4 or claim 5~~ and bringing an effective amount of said F protein into combination or association with a physiologically acceptable carrier.
8. (Currently amended) Purified RSV F protein produced by the process of ~~any one of claims 4 to 6~~ claim 4.
9. (Original) Respiratory syncytial virus (RSV) fusion (F) protein, produced by a process comprising:  
growing RSV mutant strain *cpts-248/404* on eukaryotic cells in a cultured medium at 30°C;  
solubilizing the F protein from the separated virus; and  
isolating and purifying the solubilized F protein by ion-exchange chromatography.
10. (Original) The isolated RSV F protein of claim 9, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
11. (Original) A process for producing purified RSV G protein comprising:  
growing eukaryotic cells infected with the RSV mutant strain *cpts-248/404* in a cultured medium at 30°C;  
solubilizing the G protein from the virus-infected cell membrane; and  
isolating and purifying the solubilized G protein.
12. (Original) The process of claim 10, wherein the isolating and purifying is effected by loading the solubilized G protein onto ion-exchange and affinity matrixes, and eluting the G protein from the matrixes.

13. (Original) The process of claim 10, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
14. (Currently amended) A process for producing an immunogenic composition for protecting against disease caused by RSV, wherein said process comprises producing an RSV G protein by a process according to ~~any one of claims 11 to 13~~ claim 11 and bringing an effective amount of said G protein into combination or association with a physiologically acceptable carrier.
15. (Currently amended) Purified RSV G protein produced by the process of ~~any one of claims 11 to 13~~ claim 11.
16. (Original) Respiratory syncytial virus (RSV) attachment (G) protein, produced by a process comprising:  
growing RSV mutant strain *cpts-248/404* on eukaryotic cells in a cultured medium at 30°C;  
solubilizing the G protein from the separated virus; and  
isolating and purifying the solubilized G protein by ion-exchange and affinity chromatography.
17. (Original) The isolated RSV G protein of claim 16, wherein the eukaryotic cells are VERO, MRC-5, FRhL, CEF or PER.C6 cells.
18. (Canceled)